Samsung Biologics revenue and financials

207940 · KRX · KRW

₩1,277,000.00−2.52%−₩33,000.00

Close · October 7, 2026

In the fiscal year ended December 2025, Samsung Biologics reported revenue of ₩4.56T (+30.31% year over year). Net income was ₩1.78T, a net margin of 39.2%.

Annual revenue · 2025: ₩4.56T
  1. ₩1.57T2021
  2. ₩3T2022
  3. ₩3.69T2023
  4. ₩3.5T2024
  5. ₩4.56T2025

Fiscal year ending in December. Sources and method on the page Methodology and sources.

At a glance

Revenue growth
+30.31%
2025 vs 2024
Net income growth
+64.71%
2025 vs 2024
Net margin
39.2%
2024: 31.0%

Financial data

Amounts in millions of KRW; per-share values in KRW; shares in millions.

ItemQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023Q3 2023
Total assets12,652,62111,995,00011,060,74218,337,30417,773,64417,436,97717,336,29616,026,34016,342,85116,523,19216,046,19715,887,670
Current assets5,331,1464,660,7504,408,3676,361,6385,708,9165,263,2295,518,1184,808,8955,431,3535,602,2005,521,9885,426,433
Cash and equivalents288,576520,363148,851922,128709,479752,060391,222540,227973,5101,060,081367,937279,185
Short-term investments1,924,3631,132,5911,336,2321,037,922935,210533,176940,067447,884595,0641,000,0731,688,3381,538,207
Receivables615,771566,425676,467——-0.0-0.0—0.0———
Inventory2,344,4062,291,5562,128,1643,124,8303,077,1862,873,4542,818,2762,686,4442,761,2652,661,1852,641,3682,551,229
Net property, plant and equipment6,748,0096,748,3106,037,5326,186,6896,219,3066,263,8285,837,4825,149,5614,820,1904,794,3814,342,4244,272,916
Goodwill———1,677,6081,677,6081,677,6081,677,6081,677,6081,677,6081,677,6081,677,6081,677,608
Other intangible assets76,79475,67260,1931,042,6311,025,1331,052,5681,294,7051,279,4871,522,2531,544,9411,580,4231,541,217
Long-term investments51,94473,72578,32561,20561,07876,75159,60553,39642,84942,60947,43546,335
Current liabilities2,966,1472,740,0142,532,9173,771,3113,643,9613,619,0943,853,1883,563,7604,034,0774,646,0784,157,8614,107,626
Accounts payable182,538213,61959,814253,647215,714184,279177,992191,195168,672187,286201,709164,492
Long-term debt599,228599,101599,012893,4011,058,1301,057,9231,012,757214,832244,815194,801239,783349,469
Total debt1,241,2751,194,488927,0941,221,6201,417,877———————
Total liabilities4,290,6984,072,1643,609,6316,157,8866,170,8506,156,8696,431,6205,434,7906,014,5276,512,9556,215,7056,341,650
Total equity (incl. minority)8,361,9237,922,8367,451,11112,179,41811,602,79411,280,10910,904,67610,591,54910,328,32410,010,2389,830,4929,546,020
Retained earnings7,770,8607,340,2066,870,9616,361,0085,786,5485,462,1625,086,6094,765,1154,500,6474,182,6554,003,2933,712,609